Efficacy and Safety of Dacomitinib in the Treatment of Skin Squamous Cell Cancer

Summary

This is an open label, monocentric, uncontrolled phase II trial with Dacomitinib, a pan-HER inhibitor, in unresectable or metastatic skin SCC. HER2 expression is common in skin SCC, being reported with high rates, even if in small studies. Coexpression of EGFR, HER2 and HER3 is present in skin SCCs but not in normal skin and it could be associated with the malignant phenotype. In this frame Dacomitinib could play a role in the increase of the response rate.

Timeline

Start

2014-11

Primary completion

2016-11

Completion

2016-11

Drugs

Indications